XML 23 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2020
Fair Value Measurements [Abstract]  
Fair Value Measurements
4.  Fair Value Measurements


We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly-held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. We classify most of our securities as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices.


The following tables present the major security types we held at June 30, 2020 and December 31, 2019 that we regularly measure and carry at fair value. At June 30, 2020 and December 31, 2019, a portion of our ProQR investment was subject to trading restrictions that extend to the fourth quarter of 2020; as a result, we included a lack of marketability discount in valuing this investment, which is a Level 3 input. The amount we owned in ProQR did not change from December 31, 2019 to June 30, 2020. The tables below segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective securities’ fair value (in thousands):

 
At
June 30, 2020
   
Quoted Prices in
Active Markets
(Level 1)
   
Significant Other
Observable Inputs
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
Cash equivalents (1)
 
$
363,019
   
$
363,019
   
$
   
$
 
Corporate debt securities (2)
   
1,150,959
     
     
1,150,959
     
 
Debt securities issued by U.S. government agencies (3)
   
259,505
     
     
259,505
     
 
Debt securities issued by the U.S. Treasury (4)
   
385,651
     
385,651
     
     
 
Debt securities issued by states of the U.S. and political subdivisions of the states (5)
   
119,744
     
     
119,744
     
 
Other municipal debt securities (3)
   
909
     
     
909
     
 
Investment in ProQR Therapeutics N.V. (6)
   
2,390
     
684
     
     
1,706
 
Total
 
$
2,282,177
   
$
749,354
   
$
1,531,117
   
$
1,706
 

 
At
December 31, 2019
   
Quoted Prices in
Active Markets
(Level 1)
   
Significant Other
Observable Inputs
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
Cash equivalents (1)
 
$
418,406
   
$
418,406
   
$
   
$
 
Corporate debt securities (7)
   
1,102,568
     
     
1,102,568
     
 
Debt securities issued by U.S. government agencies (8)
   
329,404
     
     
329,404
     
 
Debt securities issued by the U.S. Treasury (3)
   
363,694
     
363,694
     
     
 
Debt securities issued by states of the U.S. and political subdivisions of the states (3)
   
40,407
     
     
40,407
     
 
Investment in ProQR Therapeutics N.V. (6)
   
4,506
     
     
     
4,506
 
Total
 
$
2,258,985
   
$
782,100
   
$
1,472,379
   
$
4,506
 

The following footnotes reference lines on our condensed consolidated balance sheet:

(1)
Included in cash and cash equivalents.

(2)
$32.4 million was included in cash and cash equivalents, with the difference included in short-term investments.

(3)
Included in short-term investments.

(4)
$59.7 million was included in cash and cash equivalents, with the difference included in short-term investments.

(5)
$6.2 million was included in cash and cash equivalents, with the difference included in short-term investments.

(6)
Included in other current assets.

(7)
$19.0 million was included in cash and cash equivalents, with the difference included in short-term investments.

(8)
$0.8 million was included in cash and cash equivalents, with the difference included in short-term investments.

Convertible Notes


Our 1% Notes and 0.125% Notes had a fair value of $340.5 million and $536.5 million at June 30, 2020, respectively. We determine the fair value of our notes based on quoted market prices for these notes, which are Level 2 measurements because the notes do not trade regularly.